First Ultrasound Contrast Agent Approved by FDA for Liver Imaging
FDA approves first contrast agent for enhanced ultrasonography of the liver
By John Hocter
Bracco Diagnostics announced today that its Lumason ultrasound contrast agent has received FDA approval for use in enhanced liver ultrasound in both adult and pediatric patients.
The announcement makes Lumason the first ultrasound contrast agent approved for liver imaging, said Alberto Spinazzi, MD, a senior vice president for the Milan-based company.
Continue reading this entire article: